Protalix BioTherapeutics, Inc.

PLX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Assets
Cash & Equivalents $51.2M $63.3M $76.4M $54.8M $86.4M $52.0M $27.0M $35.9M
Accounts Receivable $1.7M $693.0K $1.9M $2.1M $1.4M $1.4M $7.0M
Inventory $7.8M $5.2M $5.8M $3.5M $8.0M $4.0M $279.0K $1.2M
Total Current Assets $62.7M $71.9M $85.9M $65.5M $97.9M $61.2M $32.5M $46.3M
Property, Plant & Equipment $7.7M $8.7M $9.7M $11.3M $13.7M $16.3M $18.3M $17.5M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $72.2M $82.2M $97.3M $78.4M $113.3M $78.7M $51.8M $64.7M
Liabilities
Accounts Payable $9.3M $7.5M $5.5M $6.8M $5.3M $5.3M $5.0M $6.3M
Total Current Liabilities $22.8M $66.2M $11.2M $64.4M $26.7M $25.8M $18.7M $18.9M
Long-Term Debt $912.0K $2.4M $5.4M $6.6M
Total Liabilities $101.7M $92.2M $86.4M $134.0M $140.3M $82.1M $77.9M $76.1M
Stockholders' Equity
Retained Earnings $-296.1M $-212.7M $-183.3M $-241.3M $-211.4M $-183.6M $-172.0M $-135.4M
Total Stockholders' Equity $-29.5M $-10.0M $10.9M $-55.6M $-26.9M $-3.4M $-26.1M $-11.3M
← Newer Page 2 of 2 Older →